ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO455

Impact of Multimorbidity on Patient-Reported Quality of Life – Analysis of a Real World CKD Patient Population

Session Information

Category: Chronic Kidney Disease (Non-Dialysis)

  • 306 CKD: Cognitive Dysfunction, Depression, Quality of Life


  • Jackson, James, Adelphi Group, Macclesfield, United Kingdom
  • Hadfield, Anna, Adelphi Real World, Macclesfield, United Kingdom
  • Moon, Rebecca, Adelphi Group, Macclesfield, United Kingdom

It is widely accepted that the prevalence of anemia, secondary hyperparathyroidism (SHPT) and hyperkalemia amongst chronic kidney disease (CKD) patients increases as CKD worsens. The objective of this analysis was to determine whether an increase in the number of CKD related comorbidities has an impact on patient quality of life (QoL).


Data were drawn from the Adelphi CKD Disease Specific Programme (DSP), a real-world, cross-sectional survey of consulting non-dialysis (ND) and dialysis CKD patients across 5EU and USA. Patients were segmented according to the number of physician-reported, CKD-related comorbidities (anemia, SHPT and/or hyperkalemia) experienced and patient-reported QoL was assessed using EuroQol-5D-3L (EQ-5D).


Results from 1758 CKD patients showed that as CKD worsened, patients were more likely to experience multiple comorbid conditions (Figure 1). An increase in multimorbidity at Stage 3-ND and Stage 4-ND was associated with a decrease in patient-reported QoL. For Stage 4-ND patients, a significant reduction was observed in the mean EQ-5D score for patients with 3 conditions compared with those who have 0 conditions (Figure 1). Although a similar trend was not observed amongst the Dialysis population, the QoL scores were lower overall than those patients at an earlier stage (Figure 1).


Multimorbidity increases as CKD progresses. Increased multimorbidity is associated with a poorer quality of life for CKD patients. Slowing disease progression could help prevent the onset of anemia, SHPT and/or hyperkalemia leading to maintenance of better QoL for longer.